Clinical Trial Update: Open-label Safety Extension Study of 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults [Phase 2]

View source ↗

Summary

This update reports results from an open-label safety extension of vortioxetine (5 and 10 mg) for long-term treatment of adults with major depressive disorder (…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Vortioxetine (vortioxetine)

Snippet

Sponsor: H. Lundbeck A/S | Conditions: Major Depressive Disorder | Phase 2 | Status: COMPLETED | Results posted: 2013-12-17